Compare Axogen Inc (AXGN) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs McCormick & Company, Incorporated — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while McCormick & Company, Incorporated trades at $52.85 (market cap $14.21B). The key difference: McCormick & Company, Incorporated is far larger — about 6.9× Axogen Inc's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | MKC | |
|---|---|---|
Market Cap | $2.06B | $14.21B |
Sector | Technology | Consumer Staples |
52-Week High | $46.19 | $72.81 |
52-Week Low | $11.28 | $45.60 |
Enterprise Value | $1.98B | $18.81B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
McCormick (MKC) trades at $53.75, up 2.48% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, while valuation metrics like a P/E of 8.94 appear attractive. Recent Q2 2026 earnings beat estimates, and the company reaffirmed its 2026 outlook, supported by the transformative Unilever Foods deal announced in July 2026.
Outlook is positive with a consensus price target of $59.67 offering 11% upside, driven by margin recovery and strategic acquisitions. Risks include soft consumer volumes in the Americas and integration challenges from the Unilever deal. The stock presents a value opportunity with a 4% dividend yield, but investors should monitor volume trends and deal execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
